Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan

Background: The cost-effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease (CKD) has not been evaluated in Japan, so we analyzed the cost-effectiveness of dapagliflozin, an SGLT2 inhibitor, for CKD stages 3a and 3b.Methods and Results: We used the Markov model...

Full description

Saved in:
Bibliographic Details
Published in:Circulation Journal 2022/11/25, Vol.86(12), pp.2021-2028
Main Authors: Kodera, Satoshi, Morita, Hiroyuki, Nishi, Hiroshi, Takeda, Norifumi, Ando, Jiro, Komuro, Issei
Format: Article
Language:English
Subjects:
Chronic kidney disease
Cost-Benefit Analysis
Glucosides - therapeutic use
Humans
ICER
Japan
QALY
Renal Insufficiency, Chronic - drug therapy
SGLT2 inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The cost-effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease (CKD) has not been evaluated in Japan, so we analyzed the cost-effectiveness of dapagliflozin, an SGLT2 inhibitor, for CKD stages 3a and 3b.Methods and Results: We used the Markov model for CKD to assess the costs and benefits associated with and without dapagliflozin from a health system perspective. We estimated the incremental cost-effectiveness ratio (ICER), expressed as per quality-adjusted life-years (QALYs). An ICER
ISSN:1346-9843
1347-4820
1347-4820
DOI:10.1253/circj.CJ-22-0086